BeiGene Ltd ADR Stock
Your prediction
BeiGene Ltd ADR Stock
We can see a decrease in the price for BeiGene Ltd ADR. Compared to yesterday it has lost -€4.000 (-1.460%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for BeiGene Ltd ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of BeiGene Ltd ADR in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of BeiGene Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| BeiGene Ltd ADR | -1.460% | -2.158% | -16.564% | 58.140% | 58.140% | 38.071% | 43.915% |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
Comments
BeiGene, Ltd. (NASDAQ: BGNE) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $300.00 price target on the stock.
Show more
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $200.00 to $235.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat